Financial Performance - The net profit attributable to the parent company for 2024 is CNY 243,525,296, with the parent company achieving a net profit of CNY 161,150,457.99[6]. - The company's operating revenue for 2024 was CNY 3,982,577,119.73, a decrease of 13.02% compared to 2023[23]. - Net profit attributable to shareholders for 2024 was CNY 243,525,296.00, down 19.73% from the previous year[23]. - The net profit after deducting non-recurring gains and losses increased by 54.54% to CNY 214,624,949.50 compared to 2023[23]. - The total profit for the year was CNY 346 million, down 16.14% compared to the previous year[68]. - The company’s net assets attributable to shareholders grew by 2.24% to CNY 4.11 billion[68]. - The company reported a significant reduction in short-term borrowings by 69.92%, down to CNY 212,116,144.16, as a result of repaying bank loans[95]. Dividend Distribution - The total cash dividend for the year, including the interim distribution, amounts to CNY 111,822,565.25, representing 45.92% of the net profit attributable to shareholders[7]. - The proposed cash dividend distribution is CNY 0.6 per 10 shares, totaling CNY 60,994,126.50, subject to shareholder approval[6]. - The company announced a cash dividend of CNY 111,822,565.25, which accounts for 45.92% of the net profit attributable to ordinary shareholders in the consolidated financial statements, amounting to CNY 243,525,296.00[195]. - The cumulative cash dividend over the last three accounting years is CNY 213,479,442.75, with an average net profit of CNY 197,455,937.04, resulting in a cash dividend ratio of 108.11%[197]. Assets and Liabilities - Total assets at the end of 2024 were CNY 6,000,330,923.23, a decrease of 23.25% from the end of 2023[23]. - The company’s cash and cash equivalents increased by 70.04% to CNY 2,947,718,857.86, primarily due to the receipt of remaining payments from the real estate business divestiture[95]. - Accounts receivable decreased by 38.09% to CNY 42,208,300.08, mainly due to the settlement of notes[95]. - The remaining undistributed profit for the parent company is CNY 478,213,079.30, to be carried forward to future years[6]. Research and Development - The company invested 199 million yuan in R&D in 2024, representing a year-on-year increase of 20.05%[38]. - The number of R&D personnel is 430, accounting for 11.85% of the total workforce[89]. - Total R&D investment amounted to 198.72 million RMB, which is 4.99% of total revenue, with 16.08% of R&D costs capitalized[88]. - The company launched over 140 new cosmetic products and received 64 new patent authorizations, including 42 invention patents[38]. Market Performance - In 2024, the cosmetics segment achieved revenue of 2.475 billion yuan, a year-on-year increase of 2.46%, with a gross margin of 62.57%[35]. - The Yilian brand generated revenue of 963 million yuan, up 12.36% year-on-year, while the Ai'er Doctor brand saw a revenue decline of 3.48% to 1.301 billion yuan[35]. - The pharmaceutical segment reported revenue of 512 million yuan, a decrease of 1.41%, with a gross margin of 52.32%[36]. - The company achieved a sales growth of 37% for its Tongxuan Li Fei capsules, with over 360,000 boxes sold[36]. Corporate Governance - The company held two shareholder meetings during the reporting period, ensuring all shareholders, especially minority shareholders, could exercise their voting rights[154]. - The board of directors convened 9 meetings during the reporting period, maintaining compliance with legal and regulatory requirements[154]. - The company emphasizes the importance of intellectual property protection and the commercialization of research outcomes[52]. - The company’s governance structure includes independent directors and supervisors to ensure compliance and accountability[168]. Strategic Initiatives - The company is focused on technological innovation and high-end transformation in the raw materials sector, driven by the increasing demand for natural and green ingredients[45]. - The company is actively expanding its market presence through strategic partnerships and product innovation, aiming to capture emerging market opportunities in both cosmetics and pharmaceuticals[44]. - The company is implementing a "1234" high-quality innovation development strategy, focusing on enhancing its leading position in hyaluronic acid and optimizing its pharmaceutical and cosmetics segments[135]. - The company is committed to integrating raw material and formulation development, accelerating the registration of pharmaceutical-grade hyaluronic acid domestically and internationally[137]. Environmental and Social Responsibility - The company emphasizes environmental protection and safety management, committing to enhance training and risk control measures[150]. - The company is committed to green development and increasing investment in environmental protection to ensure compliance with emission standards[150]. - The company is closely monitoring policy changes in the cosmetics and pharmaceutical sectors to mitigate potential risks and adapt its strategies accordingly[145]. Human Resources - The total number of employees across the parent company and major subsidiaries is 3,630, with 1,235 in production, 560 in sales, and 1,280 in technical roles[184][185]. - The company has established a talent development mechanism to enhance the quality of its workforce and ensure a steady supply of key personnel[187][188]. - The company has implemented a performance-based salary system, linking compensation to operational performance and market competitiveness[186].

证券代码：600223 证券简称：福瑞达 编号：临 2025-004 鲁商福瑞达医药股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次利润分配方案不触及《上海证券交易所股票上市规则（2024 年 4 月 修订）》第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配预案内容 （一）利润分配方案的具体内容 经上会会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于母 公司所有者的净利润 243,525,296.00 元，母公司 2024 年度实现净利润 161,150,457.99 元，母公司期末可供股东分配的利润为 539,207,205.80 元。 ●每股派发现金红利人民币 0.06 元(含税)。 ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。 ●在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额 不变，相应调整每股分配比例，并另行公告具体调整情况。 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-001 鲁商福瑞达医药股份有限公司 2025 年度"提质增效重回报"行动方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为践行中央经济工作会议和中央金融工作会议精神，落实国务院《关于进一 步提高上市公司质量的意见》要求，响应上海证券交易所《关于开展沪市公司"提 质增效重回报"专项行动的倡议》，推动上市公司高质量发展和投资价值提升， 鲁商福瑞达医药股份有限公司（以下简称"公司"）制定了《2025 年度"提质 增效重回报"行动方案》，具体方案如下所示： 一、聚焦主责主业，提升经营质量 近年来，公司通过实施重大资产出售，剥离房地产开发业务，聚焦于化妆品、 医药、原料及添加剂等业务，实现了业务平稳转型、盈利稳健增长、资产持续改 善。2024 年，公司紧紧围绕战略规划和年度经营计划，稳步推进各业务板块的 生产经营，进一步加大科技创新投入力度，积极推进智能化、数字化、绿色化转 型升级，持续提升品牌影响力，务实前行、克难攻坚，不断激发经营活力和增长 动力，推进各项经营管 ...

证券代码：600223 证券简称：福瑞达 编号：临 2024-043 鲁商福瑞达医药股份有限公司 关于控股股东非公开发行可交换公司债券 部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●截止本公告发布之日，控股股东山东省商业集团有限公司（以下简称"鲁 商集团"）直接持有鲁商福瑞达医药股份有限公司（以下简称"公司"）股份 524,739,200 股，占公司总股本的 51.62%；鲁商集团及一致行动人合计持有公司 股份 551,785,200 股，占公司总股本的 54.28%。 规要求及时履行信息披露义务。 ●公司于 2024 年 12 月 25 日接到控股股东鲁商集团通知，鲁商集团于 2024 年 12 月 25 日在中国证券登记结算有限责任公司上海分公司办理完成了"山东省 商业集团有限公司-2021 年面向专业投资者非公开发行可交换公司债券（第二 期）质押专户"持有的本公司 35,000,000 股股票解除质押手续。 ●本次股份解除质押后，鲁商集团累计质押股份 140,000,000 ...

各位投资人大家早上好我是身为宏远证券的研究员王丽萍今天和我一起主持佛罗里达电话会的还有我们不完品英美的高级研究员王盼今天我们也是非常荣幸能邀请来佛罗里达的AI张总佛罗里达也是我们非常看好的公司我们觉得目前来看也是属于被低估的因此我们也是希望通过这个交流让更多投资人来了解佛罗里达来发现公司的价值 可能数据上会稍微有点放缓了我觉得但是总体来讲也还卖的也还可以包括他前段时间添的那个短带啊那个效果都不错呃我想着反正定期这个嗯可能更新来讲就是没有什么很大的情况要不大家都比较熟悉让我们直接直接定期为环节看看大家有什么问题那个那个想想想来问的 建立一个私有的这种联系那其实对我们品牌建立是很大的一个帮助因为我们是一个做科研做品牌这么一个企业嘛所以这个对我们来说长远来看是一个非常好的一个行为再加上今年确实线下这一块整体表现的数据是不错的不管是说我们这个线下店拓展的速度啊还是说这个整个线下的一个销售情况应该都还是比较不错的以上 请参会人员务必注意本次电话会议交流内容仅限参会人员内部参考任何机构或个人不得以任何形式对电话会议任何内容进行泄露或外发请勿以任何方式索要泄露散布转发电话会议纪要任何泄露电话会议纪要等信息的行为均为侵权行为 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2021 年 12 月，鲁商福瑞达医药股份有限公司（以下简称"公司"）控股股 东山东省商业集团有限公司（以下简称"鲁商集团"）非公开发行可交换公司债 券（第二期），并将其持有的本公司 35,000,000 股无限售流通股划转至鲁商集 团在中国证券登记结算有限责任公司上海分公司开立的质押专户"山东省商业集 团有限公司-2021 年面向专业投资者非公开发行可交换公司债券（第二期）质押 专户"，预备用于可交换公司债券换股和本息偿付提供担保。 近日，公司接到控股股东鲁商集团通知，山东省商业集团有限公司 2021 年 面向专业投资者非公开发行可交换公司债券（第二期）已于 2024 年 12 月 10 日 到期完成摘牌，累计换股 0 股。鉴于本期可交换债券已到期并完成摘牌工作，鲁 商集团拟向中国证券登记结算有限责任公司上海分公司申请办理质押专户中 35,000,000 股股份的解除质押手续。上述股份将在解除质押后划转至鲁商集团 的自有证券账户。 证券代码：600223 证券简称：福瑞达 ...

证券代码：600223 证券简称：福瑞达 编号：临 2024-041 鲁商福瑞达医药股份有限公司 关于参加 2024 年三季度沪市主板美妆行业专场集体 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2024 年 11 月 26 日（星期二）至 12 月 2 日（星期一）16:00 前通过公司邮箱 lsfrd600223@163.com 进行提问，公司将在 本次说明会上对投资者普遍关注的问题进行回答。 鲁商福瑞达医药股份有限公司（以下简称"公司"）已于 2024 年 10 月 29 日 披露公司 2024 年第三季度报告，详见上海证券交易所网站（www.sse.com.cn）。 为了便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状 况，公司计划于 2024 年 12 月 3 日参加 2024 年三季度沪市主板美妆行业专场集 体业绩说明会，会议时间下午 13:30-17:00，会上将就投资者关心的问题进行交 流。 一、业绩说明会类型 本次业绩 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][6]. Core Insights - In Q3 2024, the company achieved revenue of 877 million yuan, a year-on-year decrease of 4.8%, and a net profit attributable to shareholders of 44 million yuan, down 7.8% year-on-year [3]. - The cosmetics and raw materials business faced temporary pressure, but the pharmaceutical business showed signs of recovery with a 20% year-on-year revenue increase, primarily due to price adjustments and sales channel management [3][4]. - The overall profitability improved, with a slight decrease in net profit margin by 0.2 percentage points year-on-year, attributed to effective cost control in sales and management expenses [4]. Summary by Sections Business Performance - The cosmetics business saw a revenue decline of 4.7% year-on-year, with specific brand performances varying: Yilian down 4%, Aier Doctor down 11%, while other brands increased by 42%. Gross margin improved by 4.3 percentage points due to product structure upgrades [3]. - The pharmaceutical segment's revenue growth was driven by price adjustments, although gross margin decreased by 2.0 percentage points. Investment income from Bausch + Lomb reached 9.43 million yuan, up 45,000 yuan year-on-year [3]. - The raw materials business experienced a revenue decline of 6.9%, but gross margin improved by 2.7 percentage points [3]. Financial Projections - The company expects EPS of 0.25, 0.31, and 0.34 yuan per share for 2024, 2025, and 2026 respectively, reflecting a positive outlook based on brand upgrades and pricing strategies [5]. - The current stock price is 6.94 yuan, with a total share capital of 101.657 million shares and a net asset per share of 4.02 yuan [6]. Market Position - The company is focusing on enhancing its main brands and optimizing channel structures, which is expected to contribute to overall profitability improvements [5].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the near term [3]. Core Views - The company has experienced a phase of adjustment in its cosmetics segment but is achieving steady growth, with pharmaceutical sales stabilizing in Q3 2024 [3]. - For the first three quarters of 2024, the company reported revenue of 2.803 billion yuan, a year-on-year decrease of 17.45%, while the net profit attributable to shareholders was 171 million yuan, down 28.09% year-on-year [2]. - The cosmetics segment showed a revenue increase of 3.25% year-on-year, reaching 1.708 billion yuan, with a gross margin of 62.32% [2]. - The company is focusing on multi-brand development and actively launching new products to meet market demand [2]. Summary by Sections Financial Performance - In Q3 2024, the company achieved revenue of 877 million yuan, a decrease of 4.82% year-on-year, with a net profit of 44 million yuan, down 7.76% year-on-year [2]. - The gross margin for Q3 was 51.81%, a decrease of 3.10 percentage points year-on-year, while the net profit margin was 5.01%, down 0.16 percentage points [2]. - The company’s total assets were reported at 6.10149 billion yuan, with net assets of 4.08441 billion yuan [1]. Segment Performance - The cosmetics segment's revenue for the first three quarters was 1.708 billion yuan, with notable growth in specific product lines such as the Yilian brand, which saw a 7.57% increase in revenue [2]. - The pharmaceutical segment reported revenue of 370 million yuan, a year-on-year decrease of 7.42%, but Q3 sales showed an 18.96% increase [2]. - The raw materials and additives segment generated revenue of 249 million yuan, with a slight decrease of 1.96% year-on-year [2]. Future Outlook - The company expects to achieve net profits of 282 million yuan in 2024, with projections of 327 million yuan and 373 million yuan for 2025 and 2026, respectively [3]. - Earnings per share (EPS) are projected to be 0.28 yuan in 2024, increasing to 0.32 yuan in 2025 and 0.37 yuan in 2026 [3]. - The report emphasizes the company's strategy to enhance its main brands and develop new products to adapt to market needs [2].

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [1] Core Views - The report highlights that the company experienced a revenue decline of 17.45% year-on-year for the first three quarters of 2024, totaling 2.803 billion yuan, with a net profit attributable to shareholders of 171 million yuan, down 28.09% year-on-year. However, the non-recurring net profit increased by 40.09% year-on-year to 151 million yuan [3][4] Summary by Sections Market Performance - The company's stock closed at 7.33 yuan on November 7, 2024, with a 52-week price fluctuation between 5.74 and 10.69 yuan. The total market capitalization is 7.451 billion yuan [1] Financial Performance - For Q3 2024, the company reported a revenue of 877.19 million yuan, a decrease of 4.82% year-on-year, and a net profit of 43.91 million yuan, down 7.76% year-on-year. The gross margin for Q3 was 51.81%, a decline of 3.10 percentage points year-on-year [4][8] - The cosmetics segment generated 1.708 billion yuan in revenue, up 3.25% year-on-year, while the pharmaceutical segment saw a revenue of 370 million yuan, down 7.42% year-on-year [4][6] Operational Review - The company has made strides in its raw materials segment by solidifying its leading position in hyaluronic acid and launching new products. The cosmetics segment has seen innovative sales strategies, contributing to revenue growth [6][7] Financial Forecast - The company is projected to generate revenues of 4.279 billion yuan in 2024, with a year-on-year decline of 6.6%, followed by growth in subsequent years to 4.805 billion yuan in 2025 and 5.307 billion yuan in 2026 [5][11] - The estimated net profit for 2024 is 275 million yuan, reflecting a 9.4% decrease year-on-year, with expectations of recovery in the following years [7][11] Valuation - The report suggests a price-to-earnings (P/E) ratio of 20-25 times for 2025, indicating a market capitalization range of 7.2 to 9 billion yuan, with a reasonable price range of 7.10 to 8.88 yuan per share [7][10]